Riwaroksaban — nowy lek plejotropowy o szerokim spektrum działań
Streszczenie
Doustne antykoagulanty niebędące antagonistami witaminy K (NOAC) są lekami, które stosunkowo niedawno wprowadzono do praktyki klinicznej, ale okazały się niezwykle skuteczne i bardzo chętnie oraz szeroko stosowane. Doskonale znana jest skuteczność NOAC, w tym riwaroksabanu, w zapobieganiu udarowi mózgu oraz incydentom zakrzepowo-zatorowym w grupach pacjentów z wielorakimi wskazaniami do leczenia przeciwzakrzepowego. Riwaroksaban wykazuje nie tylko pożądany wpływ na procesy zakrzepowo-zatorowe, ale prawdopodobnie powoduje również wiele działań plejotropowych, które łączą się z ograniczeniem uszkodzenia naczyń krwionośnych związanym z występowaniem czynników ryzyka sercowo-naczyniowego, oraz wykazuje potencjał hamowania rozwoju zmian miażdżycowych. W poniższym opracowaniu przedstawiono najnowszą wiedzę dotyczącą nowych potencjalnych wskazań do stosowania tego leku.
Słowa kluczowe: riwaroksabanleczenie przeciwzakrzepowedziałanie plejotropowe
Referencje
- Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013; 15(5): 625–651.
- Heidbuchel H, Verhamme P, Alings M, et al. ESC Scientific Document Group. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015; 17(10): 1467–1507.
- Kirchhof P, Benussi S, Kotecha D, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37(38): 2893–2962.
- Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor. J Thromb Haemost. 2005; 3(3): 514–521.
- Bayer Pharma AG. Xarelto (rivaroxaban) 2.5 mg film-coated tablets: EU summary of product characteristics. Bayer Pharma AG, Berlin 2013.
- Rupprecht HJ, Blank R. Clinical pharmacology of direct and indirect factor Xa inhibitors. Drugs. 2010; 70(16): 2153–2170.
- Halperin JL, Hankey GJ, Wojdyla DM, et al. ROCKET AF Steering Committee and Investigators, ROCKET AF Investigators, ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10): 883–891.
- Beyer-Westendorf J, Forster K, Pannach S, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood. 2014; 124(6): 955–962.
- Camm AJ, Amarenco P, Haas S, et al. XANTUS Investigators. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. 2016; 37(14): 1145–1153.
- Ross R, Ross R. Atherosclerosis — an inflammatory disease. N Engl J Med. 1999; 340(2): 115–126.
- Libby P. Inflammation in atherosclerosis. Nature. 2002; 420(6917): 868–874.
- Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005; 352(16): 1685–1695.
- Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med. 1999; 341(8): 586–592.
- Levi M, van der Poll T, Büller HR. Bidirectional relation between inflammation and coagulation. Circulation. 2004; 109(22): 2698–2704.
- Esmon CT. The interactions between inflammation and coagulation. Br J Haematol. 2005; 131(4): 417–430.
- Borensztajn K, Peppelenbosch MP, Spek CA. Factor Xa: at the crossroads between coagulation and signaling in physiology and disease. Trends Mol Med. 2008; 14(10): 429–440.
- Borissoff JI, Spronk HMH, Heeneman S, et al. Is thrombin a key player in the ‘coagulation-atherogenesis’ maze? Cardiovasc Res. 2009; 82(3): 392–403.
- Coughlin SR. Thrombin signalling and protease-activated receptors. Nature. 2000; 407(6801): 258–264.
- Wang D, Paria BC, Zhang Q, et al. A role for Gab1/SHP2 in thrombin activation of PAK1: gene transfer of kinase-dead PAK1 inhibits injury-induced restenosis. Circ Res. 2009; 104(9): 1066–1075.
- Hirano K. The roles of proteinase-activated receptors in the vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol. 2007; 27(1): 27–36.
- Borissoff JI, Spronk HMH, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med. 2011; 364(18): 1746–1760.
- Ragosta M, Gimple LW, Gertz SD, et al. Specific factor Xa inhibition reduces restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation. 1994; 89(3): 1262–1271.
- Ellinghaus P, Laux V, Perzborn E. Effect of rivaroxaban on thrombin-induced pro-inflammatory gene expression in human umbilical vein endothelial cells. J Thromb Haemost. 2011(9): 491.
- Ringwala SM, Dibattiste PM, Schneider DJ. Effects on platelet function of a direct acting antagonist of coagulation factor Xa. J Thromb Thrombolysis. 2012; 34(3): 291–296.
- Zhou Q, Bea F, Preusch M, et al. Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban. Mediators Inflamm. 2011; 2011: 432080.
- Hara T, Fukuda D, Tanaka K, et al. Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice. Atherosclerosis. 2015; 242(2): 639–646.
- Wu TC, Chan JS, Lee CY, et al. Rivaroxaban, a factor Xa inhibitor, improves neovascularization in the ischemic hindlimb of streptozotocin-induced diabetic mice. Cardiovasc Diabetol. 2015; 14: 81.
- Goto M, Miura SI, Suematsu Y, et al. Rivaroxaban, a factor Xa inhibitor, induces the secondary prevention of cardiovascular events after myocardial ischemia reperfusion injury in mice. Int J Cardiol. 2016; 220: 602–607.
- Imano H, Kato R, Tanikawa S, et al. Factor Xa inhibition by rivaroxaban attenuates cardiac remodeling due to intermittent hypoxia. J Pharmacol Sci. 2018; 137(3): 274–282.
- Perzborn E, Heitmeier S, Laux V. Effects of r varoxaban on platelet activation and platelet-coagulation pathway interaction: in vitro and in vivo studies. J Cardiovasc Pharmacol Ther. 2015; 20(6): 554–562.
- Mega JL, Braunwald E, Wiviott SD, et al. ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 366(1): 9–19.
- Anand SS, Bosch J, Eikelboom JW, et al. COMPASS Investigators, COMPASS investigators, COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017; 377(14): 1319–1330.
- Namba S, Yamaoka-Tojo M, Kakizaki R, et al. Erratum to: Effects on bone metabolism markers and arterial stiffness by switching to rivaroxaban from warfarin in patients with atrial fibrillation. Heart Vessels. 2017; 32(8): 983.
- Kim JB, Joung HJ, Lee JM, et al. Evaluation of the vascular protective effects of new oral anticoagulants in high-risk patients with atrial fibrillation (PREFER-AF): study protocol for a randomized controlled trial. Trials. 2016; 17(1): 422.